EGFR-TKIs have opened a crucial therapeutic avenue for EGFR-sensitive mutated non-small cell lung cancer (NSCLC) but evolution of resistance limits longer term effectiveness of these treatments, with multiple combination treatments and follow-on therapy options being explored (18). Here, EGFR is linked to non-small cell lung carcinoma.